The hijacking of T cell apoptotic pathways triggered by Gal-1, -3, and -9 provides an opportunity to target these events to enhance anti-tumor immunity, an area of interest for future anti-cancer immunotherapeutics. This evidence concerns the gene GAL and neoplasm.